ALW-II-41-27 is an ATP-competitive EPHA2 RTK inhibitor with IC50 of 11 nM.
ALW-II-41-27 reduces the number of viable NSCLC cells in a time-dependent and dose-dependent manner in vitro and induces tumor regression in human NSCLC xenografts in vivo.
ALW-II-41-27 decreases both survival and proliferation of erlotinib-resistant tumor cells and inhibits tumor growth in vivo.
ALW-II-41-27 also decreasrd viability of cells with acquired resistance to the third-generation EGFR TKI AZD9291.
